ORY-1001 is a KDM1A inhibitor (IC50 <20nM) with high selectivity against related FAD dependent aminoxidases (MAO-A B, IL4I1, KDM1B >100uM, SMOX 7uM). Treatment of THP-1 (MLL-AF9) cells with ORY-1001, results in a time dose dependent me2H3K4 accumulation a
HPG protein modifiers or p-hydroxyphenyl glyoxal react with arginine residues, producing an absorbance increase at about 340 nm, and are therefore a good choice for amino acid side chain modification.